{"organizations": [], "uuid": "ef5762d579f58dead5f02c2319096d65bcc1f7d7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s1.reutersmedia.net/resources/r/?d=20180530&i=RCV00538A&w=1200&r=RCV00538A&t=2", "site_section": "http://feeds.reuters.com/reuters/USVideoLatest", "section_title": "Reuters Video: Latest Videos US", "url": "https://www.reuters.com/video/2018/05/30/bank-stocks-still-a-good-bet-says-amy-ko?videoId=431737581", "country": "US", "domain_rank": 408, "title": "Bank stocks still a good bet, says Amy Kong", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-30T22:10:00.000+03:00", "replies_count": 0, "uuid": "ef5762d579f58dead5f02c2319096d65bcc1f7d7"}, "author": "", "url": "https://www.reuters.com/video/2018/05/30/bank-stocks-still-a-good-bet-says-amy-ko?videoId=431737581", "ord_in_thread": 0, "title": "Bank stocks still a good bet, says Amy Kong", "locations": [], "entities": {"persons": [{"name": "amy kong", "sentiment": "negative"}, {"name": "fred katayama", "sentiment": "none"}], "locations": [], "organizations": [{"name": "amy kong bank", "sentiment": "negative"}, {"name": "bank", "sentiment": "negative"}, {"name": "fiduciary trust", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Bank stocks still a good bet, says Amy Kong 3:10pm EDT - 04:49\nOne day after the sell-off in bank stocks, Fiduciary Trust's senior portfolio manager tells Reuters' Fred Katayama why she's overweight on the banking sector and why large-cap biopharma companies are ripe for M&A action.\nOne day after the sell-off in bank stocks, Fiduciary Trust's senior portfolio manager tells Reuters' Fred Katayama why she's overweight on the banking sector and why large-cap biopharma companies are ripe for M&A action. //reut.rs/2H4Tp0L", "external_links": ["https://s1.reutersmedia.net/resources/r/?d=20180530&i=RCV00538A&w=576&r=RCV00538A&t=2", "https://reut.rs/2H3lp55"], "published": "2018-05-30T22:10:00.000+03:00", "crawled": "2018-05-30T22:29:05.036+03:00", "highlightTitle": ""}